No abstract

Correlations between CY status and clinicopathological data with overall survival (OS) were analyzed. Results: Twenty-nine patients (8.1%) had positive CY (CY+) and 328 patients had negative CY (CY-). There were significant correlations between CY + and pancreatic body and tail cancer (p = 0.014), tumor extended beyond the pancreas (p = 0.023) and lymph node metastasis (p = 0.003). R0 resection rate was significantly lower in CY + group (p = 0.027). OS of CY + patients was worse than that of CY-patients (median survival time [MST], 16 vs 25 months; p = 0.003), though multivariate analysis of all patients who underwent resection did not identify CY+ as an independent prognostic factor. In CY + group, NCCN resectability status and pre-operative CA19-9 level did not have an impact on OS, however, lower SUVmax was significantly correlated with a better survival (MST, SUVmax < 4.5 vs !4.5, 35 vs 13 months; p = 0.022). Conclusion: Although the survival of patients with resected CY + PDAC is worse than that of patients with resected CY-PDAC, it is suggested that CY + patients with lower SUVmax might have better prognosis.